South Korea’s Ministry of Food and Drug Safety is also reviewing whether to grant an emergency use authorization for Merck’s antiviral COVID-19 pills, Molnupiravir.
South Korea grappled in recent months with a devastating delta-driven surge that caused a spike in hospitalizations and deaths, but transmissions have slowed after officials imposed the country’s strictest-ever virus restrictions in mid-December. The rules include a ban on private social gatherings of five or more people nationwide and a requirement that restaurants, coffee shops, gyms and karaoke venues close by 9 p.m.
But officials say the virus could regain speed in the coming weeks due to the spread of the omicron variant, which is likely to become the country’s dominant strain by the end of this month. Son Youngrae, a senior Health Ministry official, said around 12% of infections confirmed last week were of the omicron strain, which he said could account for more than 50% of cases within one or two weeks.
Experts say omicron, which has already become dominant in many countries, spreads more easily than other coronavirus strains. It also more easily infects those who have been vaccinated or had previously been infected by prior versions of the virus. However, early studies show omicron is less likely to cause severe illness than the delta variant, and that vaccination and booster shots still offer strong protection from serious illness, hospitalization and death.
The KDCA reported 4,167 new cases of the virus on Thursday, including a record 391 cases linked to international passengers. Officials say nearly 90% of cases linked to international passengers were omicron cases.
Meanwhile, in the USA the days of 'warp speed' operations for anti-COVID drugs left with the last administration. Sad!
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Newsweek - 🏆 468. / 52 Read more »
Source: bbchealth - 🏆 143. / 63 Read more »
Source: chicagotribune - 🏆 8. / 91 Read more »
Source: axios - 🏆 302. / 63 Read more »
Source: NewYorker - 🏆 90. / 67 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »